On Wednesday, Kamada (NASDAQ:KMDA) discussed first-quarter financial results during its earnings call.
The full transcript is provided below
This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https:// View the webcast at https://viavid. Summary Kamada reported first-quarter revenues and adjusted EBITDA in line with expectations, despite a temporary shipment delay, and reiterated its 2026 guidance of $200-$205 million in revenues and $50-$53 million in adjusted EBITDA.
The company’s strategic focus includes expanding its commercial product portfolio, particularly in FDA-approved specialty plasma-derived products, and enhancing its distribution segment with biosimilars in Israel and the MENA region. Operational highlights include FDA approval for a plasma collection center in Texas, plans to launch additional biosimilar products, and ongoing post-marketing research for Cytogam to increase product utilization. Management emphasized strong market demand for key products like Kedrab and Varizig, and noted efforts to secure new business development and M&A opportunities to enhance its portfolio.